Covalon signs US Distribution Agreement with Hartmann-Conco

February 11, 2005

MISSISSAUGA, ONTARIO--(CCNMatthews - Feb. 11, 2005) - Covalon
Technologies Ltd. (TSX VENTURE:COV) is extremely pleased to announce
that Covalon Technologies Inc. ("Covalon") a wholly owned subsidiary has
entered into an exclusive distribution agreement with Hartmann-Conco
Inc. ("Hartmann-Conco") to distribute Covalon collagen wound dressings
under the brand name ColActive. The agreement provides Hartmann-Conco
with exclusive distribution rights for the United States.

Covalon CEO, Dr. Frank DiCosmo said this is an extremely important
milestone for Covalon to have developed a working relationship with
Hartmann-Conco. Since there are few suppliers of collagen dressings and
since this category of wound dressings is an important one, Covalon and
Hartmann-Conco expect to have significant impact in this market through
their partnership. Dr. DiCosmo also said he is excited to be working
with an outstanding organization such as Hartmann-Conco.

Jacques M. Lemmetti, President and Chief Executive Officer of Hartmann-
Conco said he is eager to distribute Covalon's unique and innovative
medical products.

The Hartmann-Conco group comprises of several wholly-owned subsidiaries
in 36 countries and other joint venture operations. It is one of the
leading companies in its branch of industry with a sales revenue of EURO
1.3 billion in 2003 and employing 10,000 people. Hartmann-Conco is a
world-class manufacturer of wound-dressings and other surgical and
hygiene products. Hartmann-Conco is owned by Paul Hartmann AG, a major
global manufacturer of wound care products, with its head office located
in Heidenheim, Germany.

Covalon Technologies Ltd. is an advanced medical biosystems company
that has developed and patented advanced therapeutic biomaterials for
wound care and surgical applications and coatings. Polymer chemistry and
surface coating technology have been combined to create a range of
time-release drug delivery platforms that are applied to many medical
devices to treat many critical conditions. A variety of applications for
these technologies have been identified and specific products have been
developed. The products offer features and benefits providing solutions
to many of the problems caused by current devices and their material
properties which are used by most medical device manufacturers and
suppliers. The problems include infection, poor biocompatibility, and
microbial attachment.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. The TSX
Venture Exchange has in no way passed upon the merits of the proposed
transaction and has neither approved nor disapproved of the contents of
this release.

For further information please contact: William Jackson
Chief Financial Officer
Covalon Technologies Ltd.
T: (905) 568-8400
F: (905) 568-5200
www.covalon.com